Comparative Pharmacology
Head-to-head clinical analysis: MIDAZOLAM versus NIRAVAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAZOLAM versus NIRAVAM.
MIDAZOLAM vs NIRAVAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity by binding to the benzodiazepine site on GABA-A receptors, enhancing GABA's inhibitory effects, leading to increased chloride ion conductance, hyperpolarization, and neuronal inhibition.
NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.
IV: 0.5-2 mg initial, titrate by 0.5-1 mg increments every 2-3 min; typical total 2.5-5 mg. IM: 0.07-0.08 mg/kg (usual 5 mg). Oral: 7.5-15 mg as a single premedication dose.
0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.
None Documented
None Documented
Clinical Note
moderateMidazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone propionate."
Clinical Note
moderateMidazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Midazolam."
Clinical Note
moderateMidazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Midazolam."
Clinical Note
moderateMidazolam + Cyclosporine
Terminal elimination half-life: 1.5-2.5 hours in healthy adults; prolonged in elderly (5-6 hours), obesity, hepatic cirrhosis (up to 20 hours), and critical illness.
Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Renal: approximately 45-57% as metabolites (primarily 1-hydroxymidazolam glucuronide) and <1% unchanged; fecal: 2-10% via biliary excretion.
Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Midazolam."